Deep search
Search
Images
Videos
Maps
News
Shopping
Copilot
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Moderna Shares Plunge After Predicting Steep 2025 Sales Decline
The company's newer product, an RSV ( respiratory syncytial virus) vaccine, has also underperformed, contributing "minimal sales" in 2024. Analysts' concerns were heightened by the company's revised sales forecast for 2024, which projects $3 billion to $3.1 billion, falling at the low end of previous estimates.
Moderna cuts 2025 sales forecast by $1 billion on weak vaccine demand, shares fall
Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) shot and weak demand for COVID-19 vaccines, sending its shares down more than 18% in premarket trading.
Moderna shares plunge after company cuts vaccine sales outlook
The Cambridge-based company said it expects 2025 revenue of between $1.5 billion to $2.5 billion, down from its previous projection of between $2.5 billion and $3.5 billion.
Moderna shares slide after sales guidance slashed
Moderna shares dropped as much as 22 per cent on Monday after the US biotech group’s sales forecasts disappointed investors. The Boston-based company projected sales this year of $1.5bn-$2.5bn, down from a previous forecast of $2.
Moderna cuts 2025 sales forecast by $1 bln on weak vaccine demand, shares tumble
Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) shot and weak demand for COVID-19 vaccines, sending its shares down more than 24% in early trading.
Moderna Shares Drop to Five-Year Low After Slashing Revenue, Sales Forecasts
Moderna's stock plummeted to an almost five-year low after the biotech company cut its revenue outlook for this year and said that sales for last year will come in at the lower end of its guidance. Shares fell 22% to $33.
Moderna shares plunge as company dramatically lowers sales forecast
Axios Visuals Moderna shares plunged today to lows not seen since the early weeks of the pandemic after the company dramatically lowered its sales forecast. Zoom in: Waning demand for COVID vaccines is crushing Moderna's revenue.
11h
Moderna May Have The Best Shot At A Vaccine For Stomach Flu
Cases of norovirus infections are surging, but coming up with a way to prevent them has proven to be a challenge.
1d
on MSN
Moderna surprises the Street by predicting a bigger-than-expected sales drop
Shares of Moderna tumbled Monday after the vaccine maker predicted a steeper-than-expected sales drop in the new year.
14h
AI could solve greatest human challenges, if we let it, Moderna cofounder says
Combining human efforts, nature, and AI in what Noubar Afeyan calls “polyintelligence” could solve problems such as climate ...
1d
on MSN
Moderna cuts 2025 sales view on slow start to RSV shot, weak COVID vaccine demand
Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow launch of its respiratory syncytial virus (RSV) ...
1d
Moderna Stock Plunges After Vaccine Sales Struggle
Shares of Moderna plunged 20% Monday after the vaccine maker slashed its forecast of full-year 2025 revenue, as sales of its ...
1d
Moderna stock drops on lower 2025 guidance, more cost cuts
Moderna Inc. entered the new year on the heels of a worsening stock performance in 2024. The Cambridge drugmaker’s stock ...
1d
on MSN
Why Moderna Stock Just Crashed 21%
Moderna 's ( MRNA -20.49%) sales are slowing down, and Moderna stock is going down -- a lot. The coronavirus vaccine maker's ...
1d
on MSN
Moderna 2025 Revenue Guidance Below Wall Street’s Estimates
The biotech company said it expects between $1.5 billion and $2.5 billion in revenue this year, below Wall Street ...
FiercePharma
1d
JPM25: Moderna slashes guidance, plots $1B in cost cuts this year amid lackluster vaccine sales
Stéphane Bancel, CEO of mRNA specialist Moderna, delivered some difficult truths to shareholders about the company’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback